Aptevo Registers 6.9M Shares for YA Resale, Securing $25M Equity Line

TL;DR

**APVO is tapping the equity markets again, signaling ongoing cash burn and potential dilution for existing shareholders, despite a recent reverse split.**

AI Summary

Aptevo Therapeutics Inc. (APVO) filed an S-1 on October 1, 2025, to register 6,903,755 shares of common stock for resale by YA II PN, LTD. (YA). These shares are part of a Standby Equity Purchase Agreement (SEPA) dated June 16, 2025, where YA committed to purchase up to $25.0 million in common stock over 36 months. Aptevo will not receive any proceeds from YA's resale of these specific 6,903,755 shares, but may receive up to $25.0 million from direct sales to YA under the SEPA. The company paid a $25,000 structuring fee to YA and owes a 2.00% commitment fee on the $25.0 million Commitment Amount, payable in five equal quarterly installments, with the first two already paid. Aptevo is a clinical-stage biotechnology company developing bispecific immunotherapy candidates for cancer, including mipletamig in a Phase 1b/2 program for acute myelogenous leukemia and ALG.APV-527 for solid tumors. The company's common stock trades on the Nasdaq Capital Market under 'APVO', and on September 30, 2025, the last reported sale price was $1.45 per share, reflecting a 1-for-20 reverse stock split on May 23, 2025. The filing highlights a high degree of investment risk, including the company's ability to continue as a going concern and maintain Nasdaq listing compliance.

Why It Matters

This S-1 filing signals Aptevo's continued reliance on dilutive equity financing to fund its clinical-stage biotechnology operations, particularly through the $25.0 million Standby Equity Purchase Agreement with YA. For investors, this means potential significant dilution as YA resells shares, impacting per-share value, especially given the recent 1-for-20 reverse stock split on May 23, 2025. The capital infusion is crucial for advancing clinical candidates like mipletamig and ALG.APV-527 in the highly competitive oncology space, where funding is paramount for R&D. Employees and customers will watch for progress in the RAINIER trial and other programs, as successful clinical development is key to long-term viability and market positioning against larger biotech firms.

Risk Assessment

Risk Level: high — The S-1 explicitly states, "Investing in our securities involves a high degree of risk." Key risks include the company's ability to continue as a going concern and its failure to maintain compliance with Nasdaq's continued listing requirements. The reliance on a $25.0 million equity line with YA, where the selling stockholder is an "underwriter," indicates a need for capital that could lead to significant dilution, especially after the 1-for-20 reverse stock split on May 23, 2025.

Analyst Insight

Investors should exercise extreme caution due to the high risk profile and potential for significant dilution from the YA equity facility. Monitor APVO's cash burn rate and clinical trial progress closely, particularly for mipletamig and ALG.APV-527, as these are critical for long-term value creation. Consider the impact of the 1-for-20 reverse stock split on May 23, 2025, and the $1.45 share price on September 30, 2025, when evaluating entry points.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

$10.5 million

total Debt

$0

net Income

$-220.5 million

eps

N/A

gross Margin

N/A

cash Position

$1.1 million

revenue Growth

N/A

Key Numbers

• 6,903,755 — Shares of common stock (Being offered for resale by YA II PN, LTD.)
• $25.0 million — Commitment Amount (Aggregate gross proceeds Aptevo may receive from sales to YA under the Purchase Agreement)
• $25,000 — Structuring fee (Paid by Aptevo to YA)
• 2.00% — Commitment fee percentage (Paid by Aptevo to YA on the Commitment Amount)
• 36 months — Commitment Period (Duration of the Standby Equity Purchase Agreement with YA)
• 96% — Purchase price percentage (YA's purchase price for Advance Shares relative to VWAP)
• $1.45 — Last reported sale price per share (On Nasdaq Capital Market for APVO common stock on September 30, 2025)
• 1-for-20 — Reverse stock split ratio (Affected on May 23, 2025)
• 8,250,825 — Advance Shares (Registered on a Prior Registration Statement (File No. 333-288959))
• October 1, 2025 — Filing Date (Date of S-1 filing)

Key Players & Entities

• Aptevo Therapeutics Inc. (company) — Registrant and clinical-stage biotechnology company
• YA II PN, LTD. (company) — Selling stockholder and provider of Standby Equity Purchase Agreement
• Marvin L. White (person) — President and Chief Executive Officer of Aptevo Therapeutics Inc.
• SoYoung Kwon (person) — Senior Vice President and General Counsel of Aptevo Therapeutics Inc.
• Sean M. Donahue (person) — Legal counsel from Paul Hastings LLP
• Charles E. Phillips (person) — Legal counsel from Ellenoff Grossman & Schole LLP
• Nasdaq Capital Market (regulator) — Stock exchange where APVO common stock is listed
• Securities and Exchange Commission (regulator) — Regulatory body for S-1 filing
• mipletamig (company) — Clinical candidate in Phase 1b/2 for AML
• ALG.APV-527 (company) — Clinical candidate for solid tumor types

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: The company's ability to continue as a going concern is highly uncertain due to its history of operating losses and negative cash flows. As of September 30, 2025, Aptevo had an accumulated deficit of $220.5 million. Without additional financing, the company may not be able to meet its obligations as they come due.
• Reliance on Equity Financing [high — financial]: Aptevo relies heavily on equity financing, as evidenced by the Standby Equity Purchase Agreement (SEPA) with YA II PN, LTD. This agreement allows YA to purchase up to $25.0 million in common stock. Such reliance can lead to significant dilution for existing shareholders and may not provide sufficient capital to fund operations and development.
• Nasdaq Listing Compliance [medium — regulatory]: Aptevo's common stock is listed on the Nasdaq Capital Market, but the company faces risks related to maintaining this listing. The company's low stock price and potential for continued financial instability could lead to delisting if minimum bid price or market capitalization requirements are not met.
• Clinical Trial Risks [high — operational]: Aptevo's product candidates, including mipletamig and ALG.APV-527, are in clinical development. These trials are subject to significant risks, including unexpected adverse events, failure to demonstrate efficacy, and delays in regulatory approval. The success of the company is contingent on the successful development and commercialization of these unproven therapies.
• Commitment Fee Obligations [medium — financial]: Aptevo has agreed to pay YA II PN, LTD. a 2.00% commitment fee on the $25.0 million Commitment Amount, payable in five equal quarterly installments. Two of these installments have already been paid, representing a significant financial obligation that will impact cash flow.
• Biotechnology Market Volatility [medium — market]: The biotechnology sector is characterized by high volatility and significant risk. The success of companies like Aptevo is dependent on scientific breakthroughs, regulatory approvals, and market acceptance, all of which are subject to unpredictable factors.

Industry Context

Aptevo operates in the highly competitive and rapidly evolving clinical-stage biotechnology sector, focusing on novel cancer immunotherapies. The industry is characterized by significant R&D investment, long development timelines, and high failure rates. Companies often rely on strategic partnerships and equity financing to fund their pipeline development.

Regulatory Implications

Aptevo faces stringent regulatory hurdles common to all biotechnology firms, particularly concerning the clinical development and eventual approval of its drug candidates by agencies like the FDA. Maintaining compliance with Nasdaq listing requirements is also a critical regulatory concern, given the company's financial position.

What Investors Should Do

1. Monitor clinical trial progress and data readouts for mipletamig and ALG.APV-527.
2. Assess the company's cash burn rate and future financing needs.
3. Evaluate the dilution impact of the SEPA with YA II PN, LTD.
4. Track Nasdaq compliance status.

Key Dates

• 2025-10-01: S-1 Filing — Registers 6,903,755 shares for resale by YA II PN, LTD. under a SEPA, signaling ongoing financing activities.
• 2025-06-16: Standby Equity Purchase Agreement (SEPA) with YA II PN, LTD. — Establishes a framework for Aptevo to potentially raise up to $25.0 million over 36 months, crucial for funding operations.
• 2025-05-23: 1-for-20 Reverse Stock Split — Implemented to increase the per-share trading price, potentially aiding in Nasdaq compliance.

Glossary

Standby Equity Purchase Agreement (SEPA)

An agreement where an investor commits to purchase a certain amount of a company's stock over a specified period, at the company's discretion. (This is the primary mechanism through which Aptevo may raise capital from YA II PN, LTD., with the current S-1 registering shares for resale by YA.)

Accumulated Deficit

The total cumulative net losses of a company since its inception, minus any cumulative net profits. (Aptevo's significant accumulated deficit of $220.5 million highlights its history of unprofitability and reliance on external funding.)

Clinical-stage biotechnology company

A company focused on developing new drugs or therapies that are currently undergoing testing in human clinical trials. (Indicates that Aptevo's products are not yet approved or commercialized, carrying significant development and regulatory risks.)

Bispecific Immunotherapy

A type of cancer therapy that uses a molecule designed to bind to two different targets simultaneously, often engaging the immune system to attack cancer cells. (This is Aptevo's core technology platform, with candidates like mipletamig and ALG.APV-527 utilizing this approach.)

VWAP

Volume Weighted Average Price, a trading benchmark that represents the average price a security has traded at throughout the day, based on both volume and price. (YA's purchase price for Advance Shares is set at 96% of VWAP, indicating a discount to market price.)

Year-Over-Year Comparison

This S-1 filing focuses on registering shares for resale by YA II PN, LTD. under an existing Standby Equity Purchase Agreement (SEPA), rather than detailing operational or financial performance compared to a prior period. The company's financial situation remains precarious, with a significant accumulated deficit and ongoing reliance on equity financing. New risks related to the SEPA, including commitment fees and potential dilution, are highlighted.

Key Financial Figures

• $0.001 — #x201d;) of our common stock, par value $0.001 per share (“common stock”
• $25.0 million — ckholder. However, we may receive up to $25.0 million (the “Commitment Amount”)
• $25,000 — paid a structuring fee in the amount of $25,000 to YA, and the Company has agreed to pa
• $1.45 — stock on the Nasdaq Capital Market was $1.45 per share. Numbers in this prospectus
• $15.0 million — have sold an aggregate of approximately $15.0 million of shares of common stock to YA pursuan
• $3.66 — he Purchase Agreement equals or exceeds $3.66 per share of common stock (which repres

Filing Documents

• apvo-20251001.htm (S-1) — 1057KB
• apvo-ex5_1.htm (EX-5.1) — 28KB
• apvo-ex23_1.htm (EX-23.1) — 5KB
• apvo_exfilingfees.htm (EX-FILING FEES) — 78KB
• img57496738_0.jpg (GRAPHIC) — 13KB
• img136434150_0.jpg (GRAPHIC) — 7KB
• img136434150_1.jpg (GRAPHIC) — 14KB
• 0001193125-25-226825.txt ( ) — 1354KB
• apvo_exfilingfees_htm.xml (XML) — 14KB

SELECTED FINANCIAL DATA

SELECTED FINANCIAL DATA 10

USE OF PROCEEDS

USE OF PROCEEDS 11

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 12 SELLING STOCKHOLDER 16 PLAN OF DISTRIBUTION 18 I ncorporation of certain information by reference 20 WHERE YOU CAN FIND MORE INFORMATION 21 LEGAL MATTERS 21 EXPERTS 21 ABOUT THIS PROSPECTUS We incorporate by reference important information into this prospectus. You may obtain the information incorporated by reference without charge by following the instructions under “ Where You Can Find More Information.” You should carefully read this prospectus as well as additional information described under “ Incorporation of Certain Information by Reference ,” before deciding to invest in our securities. We have not, and the selling stockholder has not, authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the securities offered hereby, and only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of our securities. Our business, financial condition, results of operations and prospects may have changed since that date. The information incorporated by reference or provided in this prospectus contains statistical data and estimates, including those relating to market size and competitive position of the markets in which we participate, that we obtained from our own internal estimates and research, as well as from industry and general publications and research, surveys and studies conducted by third parties. Industry publications, studies and surveys generally state

View Full Filing

View this S-1 filing on SEC EDGAR